Indacaterol for the treatment of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 1, 2015, Pages 107-115

  Matera, Maria Gabriella ^a   Rogliani, Paola ^b   Cazzola, Mario ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Indacaterol; Indacaterol glycopyrronium fixed dose combination; Treatment

Indexed keywords

INDACATEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SCOPOLAMINE DERIVATIVE; TIOTROPIUM BROMIDE;

ACUTE DISEASE; ARTERIAL GAS; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; HYPERINFLATION; LUNG FUNCTION; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; GLYCOPYRROLATE; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84917706819     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.983076     Document Type: Article

References (71)

1. Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe 2014;10:110-20
2. Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010;27:150-9
3. Braido F, Baiardini I, Cazzola M, et al. Long-acting bronchodilators improve health related quality of life in patients with COPD. Respir Med 2013;107:1465-80
4. Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013;107:1481-90
5. Ágh T, Inotai A, Meszáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011;82:328-34
6. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435-41
7. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
8. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
9. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831-8
10. Cazzola M, Spina D, Matera MG. The use of bronchodilators in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 1997;10:129-44
11. Rossi A, Khirani S, Cazzola M. Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis 2008;3:521-9
12. Cazzola M, Matera MG. Novel longacting bronchodilators for COPD and asthma. Br J Pharmacol 2008;155:291-9
13. Cazzola M, Calzetta L, Matera MG. Beta2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011;163:4-17
14. Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14:775-83
15. Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010;46:139-50
16. Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis 2013;5:559-66
17. Cazzola M, Page CP, Rogliani P, Matera MG. Beta2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690-6
18. Charlton SJ. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 2009;158:165-8
19. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65
20. Chung VC, Ma PH, Hui DS, et al. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013;8:e70784
21. Cope S, Zhang J, Williams J, Jansen JP. Efficacy of once-daily indacaterol 75 g relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med 2012;12:29
22. Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res 2013;14:100
23. Cope S, Capkun-Niggli G, Gale R, et al. Comparative efficacy of indacaterol 150 g and 300 g versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of 2010chronic obstructive pulmonary disease - a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2011;6:329-44
24. Mahler DA, Buhl R, Lawrence D, McBryan D. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther 2013;26:348-55
25. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med 2013;13:26
26. Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012;37:204-11
27. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twicedaily long-acting beta -agonists for stable COPD: a systematic review. Chest 2012;142:1104-10
28. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;1:524-33
29. Jiang FM, Liang ZA, Zheng QL, et al. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung 2013;191:135-46
30. Cazzola M, Calzetta L, Page CP, Matera MG. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol 2014;10:129-37
31. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69
32. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:180-4
33. Beier J, Beeh KM, Brookman L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22:492-6
34. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011;8:340-5
35. O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105:1030-6
36. Rossi A, Centanni S, Cerveri I, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med 2012;106:84-90
37. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011;140:331-4
38. Cazzola M, Segreti A, Stirpe E, et al. Energy expenditure and impact of bronchodilators in COPD patients. Respir Med 2010;104:1490-4
39. Hataji O, Naito M, Ito K, et al. Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:1-5
40. Rogliani P, Ora J, Ciaprini C, et al. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. Respir Med 2014;108:307-13
41. Cazzola M, Santus P, Castagna F, et al. Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. Respir Med 2002;96:439-43
42. Cazzola M, Di Perna F, Noschese P, et al. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J 1998;11:1337-41
43. Hanania NA, Ambrosino N, Calverley P, et al. Treatments for COPD. Respir Med 2005;99(Suppl B):S28-40
44. Lipworth BJ. Long-acting beta2- adrenoceptor agonists: a smart choice for asthma? Trends Pharmacol Sci 2007;28:257-62
45. Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med 2013;107:107-11
46. Cazzola M, Rogliani P, Ruggeri P, et al. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med 2013;107:848-53
47. Bernasconi M, Brandolese R, Poggi R, et al. Dose - response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intensive Care Med 1990;16:108-14
48. Cazzola M, Matera MG. Long-acting beta2agonists as potential option in the treatment of acute exacerbations of COPD. Pulm Pharmacol Ther 2003;16:197-201
49. Segreti A, Fiori E, Calzetta L, et al. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther 2013;26:630-4
50. Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191-201
51. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Available from: http://www.goldcopd.org/guidelinesglobal- strategy-for-diagnosis-management. html [Last accessed 8 August 2014]
52. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Clinical Guideline Centre, London; 2010. Available from: http://guidance. nice.org.uk/CG101/Guidance/pdf/English [Last accessed 8 August 2014]
53. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
54. Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med 2010;31:321-33
55. Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2014;15:961-77
56. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
57. Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2013;26:218-28
58. Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med 2012;106:249-56
59. Matera MG, Calzetta L, Cazzola M. Beta-adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. Drugs 2013;73:1653-63
60. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013;173:1175-85
61. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-8
62. Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014;9:215-28
63. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209
64. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol - fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, doubleblind, parallel group study. Lancet Respir Med 2013;1:51-60
65. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94
66. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558-67
67. Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review. Chest 2014;146:309-17
68. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182(2):155-62
69. Dahl R, Chung KF, Buhl R, et al. INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65(6):473-9
70. Kornmann O, Dahl R, Centanni S, et al. NLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-g Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebocontrolled comparison. Eur Respir J 2011;37(2):273-9
71. Buhl R, Dunn LJ, Disdier C, et al. INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38(4):797-803